Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Aura Biosciences in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.47) for the quarter. HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' FY2027 earnings at ($1.64) EPS.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09).
Separately, Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Aura Biosciences currently has a consensus rating of "Buy" and a consensus target price of $23.00.
Check Out Our Latest Stock Report on Aura Biosciences
Aura Biosciences Stock Performance
Shares of AURA traded up $0.40 during mid-day trading on Wednesday, hitting $6.34. 3,115,195 shares of the company were exchanged, compared to its average volume of 189,867. The stock has a market cap of $316.69 million, a price-to-earnings ratio of -3.66 and a beta of 0.30. Aura Biosciences has a 1-year low of $5.77 and a 1-year high of $12.38. The company has a 50 day moving average of $7.54 and a 200-day moving average of $8.60.
Institutional Trading of Aura Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after purchasing an additional 43,897 shares during the period. State Street Corp boosted its position in Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after buying an additional 26,841 shares during the period. Geode Capital Management LLC boosted its position in Aura Biosciences by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after buying an additional 39,379 shares during the period. Wellington Management Group LLP acquired a new position in shares of Aura Biosciences in the third quarter worth $1,037,000. Finally, Franklin Resources Inc. increased its position in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock worth $15,571,000 after acquiring an additional 215,597 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 23,045 shares of company stock valued at $177,242 over the last ninety days. Company insiders own 5.40% of the company's stock.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
